Liven Pharmaceuticals Limited - Laporan Laba Rugi (TTM)

Liven Pharmaceuticals Limited
PK ˙ KASE
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Liven Pharmaceuticals Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2024
09-30
2024
12-31
2025
03-31
Revenue 89 106 121
Change (%) 19.26 13.91
% of Revenue 100.00 100.00 100.00
Cost Of Sales 64 72 83
Change (%) 11.92 15.35
% of Revenue 72.09 67.66 68.51
Gross Operating Profit 25 34 38
Change (%) 38.22 10.90
% of Revenue 27.91 32.34 31.49
SG&A 3 19 27
Change (%) 508.05 41.86
% of Revenue 3.47 17.69 22.03
R&D
Change (%)
% of Revenue
OpEx 79 102 121
Change (%) 29.52 18.44
% of Revenue 88.82 96.47 100.30
Operating Income 10 4 -0
Change (%) -62.29 -109.73
% of Revenue 11.18 3.53 -0.30
Interest Expense -0 -0
Change (%) 358.22
% of Revenue -0.00 -0.01
Net Income 139 115 108
Change (%) -17.56 -6.17
% of Revenue 156.73 108.35 89.24

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista